Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although various strategies have been proposed to treat antidepressant nonresponders, little controlled research has been published that examines prospectively the use of switching to an alternate antidepressant. METHODS: This was a multisite study in which outpatients with chronic major depression (with or without concurrent dysthymia), who failed to respond to 12 weeks of double-blind treatment with either sertraline hydrochloride (n = 117) or imipramine hydrochloride (n = 51), were crossed over or switched to 12 additional weeks of double-blind treatment with the alternate medication. Outcome measures included the 24-item Hamilton Rating Scale for Depression and the Clinical Global Impressions--Severity and Improvement scales. RESULTS: The switch from sertraline to imipramine (mean dosage, 221 mg/d) and from imipramine to sertraline (mean dosage, 163 mg/d) resulted in clinically and statistically significant improvements. The switch to sertraline treatment was associated with fewer adverse effect complaints and significantly less attrition owing to adverse effects. Although sertraline treatment also resulted in significantly higher response rates in the intent-to-treat samples (60% in the sertraline group and 44% in the imipramine group), neither the intent-to-treat remission rates nor the response and remission rates among study completers differed significantly. Moreover, after considering the effect of attrition, there were no significant treatment effects on the more comprehensive generalized estimating equation analyses of the continuous dependent measures. CONCLUSIONS: More than 50% of chronically depressed antidepressant nonresponders benefited from a switch from imipramine to sertraline, or vice versa, despite a high degree of chronicity. As in the initial trial, sertraline was generally better tolerated than imipramine. Switching to a standard antidepressant of a different class is a useful treatment strategy for antidepressant nonresponders and could be considered a standard of comparison for future studies of novel alternate strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331
Self-citationVenlafaxine for Treatment-Resistant Unipolar Depression
NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00008 · Cited by 198
Prevention of Relapse in Residual Depression by Cognitive Therapy: A Controlled Trial
Paykel, E. S., Scott, J., Teasdale, J. D., Johnson, A. L., Garland, A., Moore, R., Jenaway, A., Cornwall, P. L., Hayhurst, H., Abbott, R., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.9.829 · Cited by 20 · cited 1×
“are at high risk for subsequent relapse.(34,35) It is likely that patients with chronic depression warrant longer acutephase trials.”
Background
Cited by
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Self-citationTreatment and prevention of depression
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002) · Psychological Science in the Public Interest · doi:10.1111/1529-1006.00008 · Cited by 511
Self-citationBauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
Connolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
Self-citationHusain, M. M., Rush, A. J., Fink, M., Knapp, R., Petrides, G., Rummans, T., Biggs, M. M., O'Connor, K., Rasmussen, K., Litle, M., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0406 · Cited by 456
Self-citation(2007) · PubMed · Cited by 453
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“Thase et al 139 and Peselow et al 116 each examined switching from SSRI/SNRI medications to tricyclic antidepressants (TCAs), speci fi cally imipramine, and reported response rates of 44 – 73% in total.”
Keller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388
Self-citationPapakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Self-citationAustralian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01377.x · Cited by 257
Berlim, M. T., & Turecki, G. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.009 · Cited by 249
Ruhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230
Staging methods for treatment resistant depression. A systematic review
Ruhé, H. G., van Rooijen, G., Spijker, J., Peeters, F. P. M. L., & Schene, A. H. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.02.020 · Cited by 210
Kocsis, J. H. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.144 · Cited by 214
“There is a growing literature on the first two strategies,(11-14) including work specific to chronic depression.(15) Few data address the third option, even though it may be among the most common.”
BackgroundSelf-citationSchatzberg, A. F., Rush, A. J., Arnow, B. A., Banks, P. L. C., Blalock, J. A., Borian, F. E., Howland, R., Klein, D. N., Kocsis, J. H., Kornstein, S. G., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.5.513 · Cited by 147
Self-citationMontgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143
“, 2002; Lenox-Smith and Jiang, 2008) in which a comparison of monotherapy strategies in MDD patients who were unresponsive to firstline treatment with an antidepressant either showed no significant difference in efficacy between treatments (Nolen et al., 1988, 1993; Thase et al., 2002) or a significant difference only…”
BackgroundResultChronic depression: update on classification and treatment
Torpey, D. C., & Klein, D. N. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0074-6 · Cited by 98
Self-citationCulpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.001 · Cited by 77
Perahia, D. G. S., Quail, D., Desaiah, D., Montejo, A. L., & Schatzberg, A. F. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.07.001 · Cited by 64
“Fava and Rush, 2006), or switching within the same class or to another class of antidepressant (Peselow et al., 1989; Fava, 2000; Thase et al., 2002).”
BackgroundSelf-citationChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“After a failure with either sertraline (n=117) or imipramine (n=51), patients were assigned to a 12-week trial with the other medication and had around 50% of response on both switches [22].”
Method
Metadata
- Authors
- Thase, M. E., Rush, A. J., Howland, R. H., Kornstein, S. G., Kocsis, J. H., Gelenberg, A. J., Schatzberg, A. F., Koran, L. M., Keller, M. B., Russell, J. M., Hirschfeld, R. M. A., LaVange, L. M., Klein, D. N., Fawcett, J., & Harrison, W.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2002-03-01
- Volume
- 59
- Issue
- 3
- Pages
- 233
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2099835839
- Cited by
- 144
- References
- 4
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.